Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGAGE: AbobotulinumtoxinA + GSC in Spastic Hemiparesis
NCT02969356Phase 4Completed
- Sponsor
- Ipsen
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of abobotulinumtoxinA in spastic hemiparesis, sponsored by Ipsen. Primary endpoint: Percentage of Responder Participants According to Composite Active Range of Motion (AROM) in the Primary Treatment Target Limb. Started Dec 2016; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
spastic hemiparesis
Beyond the preview
Go deeper on NCT02969356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969356.